Vaxcyte, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Vaxcyte, Inc. (PCVX), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are PCVX insiders buying or selling?
In the last 12 months, Vaxcyte, Inc. insiders reported 0 open-market purchases ($0) and 23 sales ($12.4M) — net selling of $12.4M. Since June 2020, Trabud has recorded 219 Form 4 filings for PCVX: 4 buys ($20.7M) and 215 sells ($141.6M).
Source: SEC EDGAR Form 4
What stands out
- No Vaxcyte, Inc. insider made an open-market purchase in the last 12 months; the 23 reported open-market sales totaled $12.4M.
Key Statistics (June 2020 – Oct 7, 2026)
Total Form 4 filings
219
SEC EDGAR
Insider filers
17
Insider buys (4)
$20.7M
Insider sells (215)
$141.6M
Insider sentiment
Net sellingNet insider flow of $120.9M in net selling since June 2020, and $12.4M in net selling over the last 12 months.
Recent PCVX insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 7, 2026 | Jim Wassil | EVP, Chief Scientific Ofc, COO | Sale | 18.0K | $86.74 | $1.6M | SEC ↗ |
| Oct 7, 2026 | Elvia Cowan | SVP, Finance & CAO | Sale | 19.0K | $86.74 | $1.6M | SEC ↗ |
| Oct 2, 2026 | Jim Wassil | EVP, Chief Scientific Ofc, COO | Sale | 2.3K | $56.67 | $127.5K | SEC ↗ |
| Sep 9, 2026 | Jim Wassil | EVP, Chief Scientific Ofc, COO | Sale | 2.7K | $60.35 | $163.9K | SEC ↗ |
| Sep 2, 2026 | Jim Wassil | CHIEF OPERATING OFFICER | Sale | 3.5K | $61.07 | $212.4K | SEC ↗ |
| Aug 5, 2026 | Harpreet S. Dhaliwal | Chief Technical Ops Officer | Sale | 17.0K | $55.00 | $935.1K | SEC ↗ |
| Aug 5, 2026 | Jim Wassil | CHIEF OPERATING OFFICER | Sale | 2.3K | $53.86 | $121.2K | SEC ↗ |
| Aug 5, 2026 | Andrew Guggenhime | PRESIDENT AND CFO | Sale | 10.0K | $53.89 | $538.9K | SEC ↗ |
| Jul 28, 2026 | Grant Pickering | CHIEF EXECUTIVE OFFICER | Sale | 18.2K | $55.63 | $1.0M | SEC ↗ |
| Jul 6, 2026 | Andrew Guggenhime | PRESIDENT AND CFO | Sale | 10.0K | $57.28 | $572.8K | SEC ↗ |
| Jul 6, 2026 | Jim Wassil | CHIEF OPERATING OFFICER | Sale | 2.3K | $56.33 | $126.7K | SEC ↗ |
| Jun 26, 2026 | Grant Pickering | CHIEF EXECUTIVE OFFICER | Sale | 24.2K | $55.22 | $1.3M | SEC ↗ |
| Jun 19, 2026 | Grant Pickering | CHIEF EXECUTIVE OFFICER | Sale | 24.5K | $52.50 | $1.3M | SEC ↗ |
| Jun 19, 2026 | Andrew Guggenhime | PRESIDENT AND CFO | Sale | 10.0K | $53.00 | $530.0K | SEC ↗ |
| Jun 3, 2026 | Jim Wassil | CHIEF OPERATING OFFICER | Sale | 2.3K | $49.52 | $111.4K | SEC ↗ |
| May 1, 2026 | Jim Wassil | CHIEF OPERATING OFFICER | Sale | 2.3K | $56.83 | $127.9K | SEC ↗ |
| Apr 8, 2026 | Elvia Cowan | SVP, Finance & CAO | Sale | 3.0K | $60.00 | $180.0K | SEC ↗ |
| Apr 3, 2026 | Jim Wassil | CHIEF OPERATING OFFICER | Sale | 2.3K | $58.43 | $131.5K | SEC ↗ |
| Mar 18, 2026 | Elvia Cowan | SVP, Finance & CAO | Sale | 1.9K | $55.57 | $105.1K | SEC ↗ |
| Mar 11, 2026 | Elvia Cowan | SVP, Finance & CAO | Sale | 2.5K | $58.59 | $146.5K | SEC ↗ |
| Mar 11, 2026 | Jim Wassil | CHIEF OPERATING OFFICER | Sale | 7.4K | $58.88 | $435.4K | SEC ↗ |
| Jan 2, 2026 | Harpreet S. Dhaliwal | Chief Technical Ops Officer | Sale | 9.7K | $46.69 | $454.9K | SEC ↗ |
| Dec 29, 2025 | Elvia Cowan | SVP, FINANCE | Sale | 11.6K | $47.92 | $557.0K | SEC ↗ |
| Mar 7, 2025 | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale | 5.0K | $70.74 | $353.7K | SEC ↗ |
| Mar 4, 2025 | Jim Wassil | CHIEF OPERATING OFFICER | Sale | 8.0K | $73.27 | $586.2K | SEC ↗ |
Showing the 25 most recent of 219 Form 4 filings for Vaxcyte, Inc..
Most active PCVX insiders
- Grant Pickering57 filings
- Jim Wassil38 filings
- Andrew Guggenhime32 filings
- Jeff Fairman20 filings
- Mikhail Eydelman18 filings
Ask anything about PCVX insider activity
Use Trabud's AI agent to query Vaxcyte, Inc.'s Form 4 history in plain English — "Show me PCVX CEO purchases this year" or compare it against any other ticker.
Open the AI agentPCVX insider trading FAQ
Are Vaxcyte, Inc. insiders buying or selling?
In the last 12 months, Vaxcyte, Inc. insiders reported 0 open-market purchases ($0) and 23 sales ($12.4M) — net selling of $12.4M. Since June 2020, Trabud has recorded 219 Form 4 filings for PCVX: 4 buys ($20.7M) and 215 sells ($141.6M). Over the full record that is net selling of $120.9M.
How many insiders trade PCVX stock?
17 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Vaxcyte, Inc.. The most recent filing was accepted on Oct 7, 2026.
Where does Trabud get PCVX insider trading data?
All PCVX insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.